智通财经APP讯,石四药集团(02005)发布公告,集团的利鲁唑已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。利鲁唑主要用于延长肌萎缩侧索硬化(ALS)患者的生命,或延长其发展至需要机械通气支持的时间。
智通财经APP讯,石四药集团(02005)发布公告,集团的利鲁唑已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。利鲁唑主要用于延长肌萎缩侧索硬化(ALS)患者的生命,或延长其发展至需要机械通气支持的时间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.